Variability of sputum inflammatory mediators in COPD and α1-antitrypsin deficiency

European Respiratory Journal

Volumn 40, Issue 3, 2012, Pages 561-569

  Stone, Helen ^a   McNab, Gillian ^a   Wood, Alice M ^a   Stockley, Robert A ^a   Sapey, Elizabeth ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

1 antitrypsin deficiency; Chronic obstructive pulmonary disease; Inflammatory mediators; Sputum

Indexed keywords

INTERLEUKIN 8; LEUKOTRIENE B4; MYELOPEROXIDASE;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPUTUM ANALYSIS; SPUTUM LEVEL;

ADULT; AGED; ALPHA 1-ANTITRYPSIN DEFICIENCY; CELL COUNT; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; LEUKOTRIENE B4; MALE; MIDDLE AGED; PEROXIDASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84865830504     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00162811     Document Type: Article

References (55)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of COPD. Updated 2011. www.goldcopd.org/Guidelines/guidelines-resources.html.
2. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
3. Calverley PA, Sanchez-Toril F, McIvor A, et al. Effect of 1 year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-161. (Pubitemid 47057851)
4. Calverley PA, Anderson JA, Celli BC, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonar disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
5. Rennard SI, Calverley PM, Goethring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011; [Epub ahead of print DOI:10.1186/465-9921-12-18].
6. Burge PS, Calverley PM, Jones PW, et al. Randomised, doubleblind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. The ISOLDE trial. BMJ 2000; 320: 1297-1303. (Pubitemid 30245717)
7. Sapey E, Stockley RA. The neutrophil and its special role in chronic obstructive pulmonary disease. In: Barnes PJ, Drazen JM, Rennard SI, et al., eds. Asthma and COPD: Basic Mechanisms and Clinical Management. 2nd Edn. London, Elsevier Publishing, 2008; pp. 173-192.
8. Donaldson GC, Seemungal TA, Patal IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004. (Pubitemid 41507533)
9. Parr DG, White AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in COPD: a prospective study. Respir Res 2006; 7: 136.
10. Gompertz S, Hill AT, Bayley D, et al. Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency. Respir Med 2006; 100: 1094-1099.
11. Gompertz S, Bayley D, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36-41. (Pubitemid 32041717)
12. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926-934. (Pubitemid 39258050)
13. Gompertz S, Stockley RA. A randomised controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 112: 289-294. (Pubitemid 34754176)
14. Sapey E, Bayley D, Ahmad A, et al. Inter-relationships between inflammatory markers in stable COPD patients with bronchitis: the intra and inter patient variability. Thorax 2008; 63: 493-499. (Pubitemid 351831157)
15. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 6-14. (Pubitemid 43955238)
16. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in α1-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164: 1805-1809. (Pubitemid 33152311)
17. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002; 121: Suppl., 151S-155S. (Pubitemid 34497333)
18. Dawkins PA, Dawkins CL, Wood AM, et al. Rate of progression of lung function impairment in α1-antitrypsin deficiency. Eur Respir J 2009; 33: 1338-1344.
19. Brantly ML, Paul LD, Miler BH, et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138: 327-336.
20. Cerveri I, Brusasco V. Revisited role for mucus hypersecretion in the pathogenesis of COPD. Eur Respir Rev 2010; 19: 109-112.
21. Woolhouse IS, Bayley D, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha 1 anti-trypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002; 57: 709-714. (Pubitemid 34864528)
22. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893-898. (Pubitemid 29442027)
23. Association for Respiratory Technology and Physiology. The ARTP Practical Handbook of Respiratory Function Testing. Part One. 2nd Edn. 2009. www.artp.org.uk/en/education/artp-books/atrp-part-1-handbook.cfm.
24. Woolhouse IS, Hill SL, Stockley RA. Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. Thorax 2001; 56: 947-953. (Pubitemid 33097190)
25. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735. (Pubitemid 41448672)
26. Stockley RA, Bayley D. Validation of assays for inflammatoy mediators in sputum. Eur Respir J 2000; 15: 778-781. (Pubitemid 30196309)
27. Woolhouse IS, Bayley DL, Stockley RA. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002; 57: 667-771.
28. Snedecor GW, Cochran WG, eds. Statistical Methods. 8th Edn. Oxford, Wiley-Blackwell, 1989.
29. Voekel M, Voeke NF, MacNee W, eds. Chronic Obstructive Lung Disease. Shelton, PMPH-USA Publishing, 2008; pp. 56-60.
30. Gamble E, Qiu Y, Wang D, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J 2006; 27: 293-299. (Pubitemid 43180905)
31. Hill AT, Bayley DL, Campbell EJ, et al. Airways inflammation in chronic bronchitis: the effects of smoking and α1-anti-trypsin deficiency. Eur Respir J 2000; 15: 886-890. (Pubitemid 30321845)
32. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857. (Pubitemid 27133393)
33. Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. Respir Med 2010; 104: 763-772.
34. Selby C, Drost E, Lannan S, et al. Neutrophil retention in the lungs of pateints with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1359-1364.
35. Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007; 30: 467-471. (Pubitemid 351182069)
36. Siva R, Green RH, Brightling CE, et al. Eosinophillic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913. (Pubitemid 46711894)
37. Sapey E, Wood AM, Ahmad A, et al. TNF-α rs361525 polymorphism is associated with increased local production and downstream inflammation in COPD. Am J Respir Crit Care Med 2010; 180: 192-199.
38. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852. (Pubitemid 35178607)
39. Stansecu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration and rapid decline in FEV1 in smokers are associated with increased levels of sputum neutropils. Thorax 1996; 51: 267-271. (Pubitemid 26086470)
40. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309: 901-911.
41. Tashkin DP, Clark VA, Coulson AH, et al. The UCLA population studies of chronic obstructive respiratory disease. VIII. Effects of smoking cessation on lung function; a prospective study of a free-living population. Am Rev Respir Dis 1984; 130: 707-715. (Pubitemid 15209547)
42. Burnett D, Chamba A, Hill SL, et al. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987; 2: 1043-1046. (Pubitemid 17154783)
43. Sapey E, Stockley JA, Greenwood H, et al. Behavioural and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2011; 183: 1176-1186.
44. Woolhouse IS, Bayley DL, Lalor P, et al. Endothelial interactions of neutrophils under flow in chronic obstructive pulmonary disease. Eur Respir J 2005; 25: 612-617. (Pubitemid 40528752)
45. Sapey E, Ahmad A, Bayley D, et al. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 2009; 29: 508-516.
46. Beeh KM, Beier J, Kornmann O, et al. Long term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123: 778-783. (Pubitemid 36315493)
47. Parmer JS, Mahadeva R, Reed BJ, et al. Polymers of α1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002; 26: 723-730. (Pubitemid 34557374)
48. Dirksen A, Dijkman JH, Madsen F, et al. A randomised clinical trial of α1-antitrypsin augmentation therapy. Am J Resp Crit Care Med 1999; 160: 1468-1472.
49. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin 2011; 27: 579-588.
50. Dirksen A, Dijkman JH, Madsen F, et al. A randomised clinical trial of α1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-1472.
51. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535. (Pubitemid 26141336)
52. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333-1338.
53. Effros RM, Peterson B, Casaburi R, et al. Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects. J Appl Physiol 2005; 99: 1286-1292. (Pubitemid 43014331)
54. Pinto-Plata V, Toso J, Lee K, et al. Profliling serum biomarkers in patients with COPD. Associations with clinical parameters. Thorax 2006; 61: 23-28.
55. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19: 189-199.